Alnylam Pharmaceuticals and CAMP4 Therapeutics partner to focus on rare disease of the liver.
The deal will give the German mRNA specialist exclusive access to a unit it has worked with for the past five years.
The FDA is still holding it together during the government shutdown but could face big problems if it extends for another month and user fees dry up.
Pfizer has inked a deal with CytoReason to use its cell-centered models of the immune system for drug discovery.
Charles River teams with Atomwise in an effort to streamline research efforts to speed drugs to market.
A new study says users were favorable toward Apple’s Health Records service, though it has yet to be widely embraced.
Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO, has merged with U.S.-based Boston Biomedical Associates.
Schrödinger has snared $85 million in financing that will be used to support its computational platform and expand its pipeline.
A Cell and Gene Therapy Catapult study shows continued strong growth of advanced therapy medicinal products in the U.K.
Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs.